Among biologics, dupilumab (Dupixent), a fully human monoclonal antibody directed against the alpha subunit of the IL-4 receptor (and inhibiting IL-4 and IL-13 signalling) has been shown to be safe and effective in adolescents and adults with severe uncontrolled asthma [28–30]. The gene discussed is IL4; the disease is asthma.